OPKO Health (OPK): Rasio rega marang prakiraan pendapatan

Lambang korporat lan logo OPKO Health (OPK)

The forward P/S valuation visualizes the ratio of OPKO Health, Inc. (OPK) market capitalization to projected revenue, where the value 2.40 reflects this status. The business faces logistics disruptions and patent complexities resulting from global conflicts. High confidence in BioReference in the US is coupled with management's expectation of a swift recovery in profitability following aggressive cost optimization.

OPK (opko.com) riwayat Rega forward marang dodolan saka 04.07.2022 nganti 13.11.2026

OPK (OPKO Health Corp.): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:
Analisis fundamental perusahaan:OPK (OPKO Health)
Sampel barang OPKO Health Corp.

The restructuring of BioReference and the expansion of Rayaldee make the forward P/S of the business a key indicator of capital reallocation efficiency for OPKO Health, Inc. (OPK). This metric determines the company's market value relative to expected future sales volumes, neutralizing the time lags associated with quarterly reports. The calculation is based on the ratio of current market capitalization to projected annual revenue. An increase in this indicator signals market optimism, although it requires confirmation through the actual operational recovery of the holding.

Karo sapa OPKO Health, Inc. saingan

Rasio rega marang prakiraan pendapatan Agilent A|Multiplikator Forward P/S Quest Diagnostics Inc. DGX|ILMN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Exact Sciences Inc.|RVTY (Revvity, Inc.) - Multiplikator forward rega marang pendapatan|bio-rad.com - Rega forward marang dodolan|NNNN (Anbio) - Multiplikator Forward P/S|SHC: Rega forward marang dodolan|Multiplikator Forward P/S QDEL|CDNA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S MRVI (Maravai LifeSciences)|Multiplikator Forward P/S fulgentgenetics.com FLGT|LAB - Rasio rega marang prakiraan pendapatan|CTKB: Rasio rega marang prakiraan pendapatan|OSUR (OraSure Technologies Inc) - Multiplikator forward rega marang pendapatan|XGN: Rasio rega marang pendapatan sing dikarepake|MDXH (MDxHealth SA) - Multiplikator Forward P/S|LUCD: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan PRE (Prenetics Global)|IMDX (imdxinc.com) - Rega forward marang dodolan|Multiplikator Forward P/S TRIB (Trinity Biotech)|Rasio kapitalisasi marang dodolan sing dikarepake ProPhase Labs Corp (PRPH)|AIMD - Rasio rega marang prakiraan pendapatan|CODX (codiagnostics.com) - Kapitalisasi marang prakiraan pendapatan|HSCS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Biomerica Inc.|Multiplikator forward rega marang pendapatan CDIO|Onconetix Corporation (ONCO) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Virax Biolabs Group (VRAX)|BJDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aspira Women's Health Inc. AWH|AXDX (Accelerate Diagnostics Inc.) - Rega mangsa ngarep marang pendapatan|CNTG - Rasio rega marang prakiraan pendapatan|ENZ - Multiplikator Forward P/S|fresh2.co (FRES) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Genetic Technologies Limited|ME (23andMe) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Psychemedics Corp. PMD